Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy can make you tired. Fatigue is listed among the recognised side effects of semaglutide in clinical trial data and in the medicine's Summary of Product Characteristics. It tends to be most noticeable in the first few weeks of treatment or shortly after a dose increase, and it typically settles as your body adjusts. This is a prescription-only medicine; a qualified prescriber assesses whether it is right for you before any treatment begins. If you are wondering whether the tiredness you are feeling is normal, or when it becomes something to discuss with your clinical team, read on — these are exactly the questions worth getting straight.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial (a large phase 3 study of 2.4 mg semaglutide published in the New England Journal of Medicine) enrolled nearly 2,000 adults with obesity over 68 weeks. Fatigue was among the side effects recorded across the semaglutide arm. It was not one of the most commonly reported events (that category is firmly dominated by gastrointestinal symptoms such as nausea and diarrhoea), but it appeared with enough consistency to be included in the medicine's official safety profile. The NHS medicines page for semaglutide lists feeling tired as a side effect that some people experience. So if semaglutide is making you tired, you are not imagining it, and our page on whether taking semaglutide makes you tired explains in detail why this happens and what you can expect.
The mechanism is not entirely separate from appetite suppression. Semaglutide slows gastric emptying and reduces how much you want to eat. Early in treatment, some people eat substantially less than their usual intake before their body has fully adjusted, which can leave them running on less energy than normal. Couple that with any nausea-related disrupted sleep and the tiredness makes physiological sense. If you are using the injectable form specifically, our page on whether the semaglutide shot makes you tired looks at how the injection itself may play a role in this fatigue pattern.
For a fuller picture of the broader side-effect profile of Wegovy, including the gastrointestinal symptoms that often accompany early treatment, our clinical overview covers the detail.
Timing matters here. Tiredness on semaglutide tends to cluster around two points: the first few weeks after starting, and the days following each dose increase. Wegovy is titrated gradually (0.25 mg to begin, stepping up approximately every four weeks under prescriber guidance toward the 2.4 mg maintenance dose) and each step can bring a brief renewal of early side effects, including fatigue.
For most people, this pattern resolves within one to two weeks of settling at a given dose. The body's response to GLP-1 receptor stimulation normalises. Appetite begins to feel manageable rather than simply absent. Energy tends to stabilise. If you want a more detailed look at whether tiredness persists beyond the adjustment window, our page on whether Wegovy tiredness is constant explores that question specifically.
Practical things that can make a real difference during this window: eat at regular intervals even if portions are small, prioritise protein at each meal to maintain muscle and sustained energy, drink water consistently throughout the day, and avoid cutting sleep short. None of these is a substitute for talking to your prescriber if fatigue is significant, they are simply sensible alongside any clinical discussion.
Fatigue that is mild and fading is different from fatigue that is worsening, prolonged, or accompanied by other symptoms. Three scenarios are worth flagging to your clinical team promptly.
First, if tiredness is severe and is stopping you from functioning day to day, that is beyond what is expected from normal treatment adjustment. Second, if exhaustion is paired with severe stomach pain (particularly pain that radiates toward the back) seek urgent medical help. The MHRA issued a Drug Safety Update in January 2026 noting that acute pancreatitis, though infrequent, is a known serious risk with GLP-1 medicines; it requires prompt assessment. Third, significant vomiting or diarrhoea can cause dehydration quickly, and dehydration is itself a driver of fatigue, if you cannot keep fluids down, contact a clinician or NHS 111 the same day.
Suspected side effects from any medicine can be reported via the MHRA Yellow Card scheme, a useful tool for patients and the main way regulators track real-world safety signals after a medicine reaches the market. Our page on more serious semaglutide side effects covers the full set of warning signs worth knowing.
At nume, every repeat order is clinically re-reviewed before dispensing, there are no automatic renewals. If fatigue is affecting your experience on Wegovy, the repeat-review step is exactly the moment to raise it. A real clinician reads your consultation, not software, and they can advise whether your tiredness fits the expected adjustment pattern or warrants a different approach. For broader questions about how Wegovy is used and monitored, our Wegovy treatment overview covers the full picture.
Wegovy is a prescription-only medicine and any decision to adjust the dose, pause treatment, or switch to a different approach sits with your prescriber. If you have not yet started and are weighing up whether this treatment suits your circumstances, a free consultation with our clinical team is the right first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.